Actions by angiotensin II on esophageal contractility in humans

Gastroenterology. 2007 Jan;132(1):249-60. doi: 10.1053/j.gastro.2006.11.010. Epub 2006 Nov 10.

Abstract

Background & aims: Angiotensin II is a potent activator of smooth muscles but has not been much investigated with regard to gastrointestinal motor activity. This study explores expression of the renin-angiotensin system (RAS) in human esophageal musculature and actions by Angiotensin II both in vitro and in vivo.

Methods: Muscular specimens of esophageal body and lower esophageal sphincter were obtained from patients undergoing resection as a result of mucosal neoplasm. Healthy volunteers participated in functional examinations of esophageal motility assessed by high-resolution manometry and multiple transmucosal potential-difference measurements.

Results: Gene transcripts of key components of RAS were found in the esophageal musculature. Immunohistochemistry revealed a distinct staining for Angiotensin II type 1 (AT(1)) receptors in the muscular bundles and blood-vessel walls, whereas Angiotensin II type 2 receptors were confined to blood vessels only. Angiotensin II caused concentration-dependent contractions in vitro, which were inhibited by the AT(1) receptor antagonist losartan but not by the Angiotensin II type 2 receptor antagonist PD123319. Administration of the AT(1) receptor antagonist candesartan reduced the amplitude of swallow-induced peristaltic contractions and both the length and pressure amplitude of baseline high-pressure zone at the esophagogastric junction. Neither swallow-induced axial movements, nor the contraction after transient lower esophageal sphincter relaxations, were influenced by candesartan pretreatment.

Conclusions: The study demonstrates a local RAS in the musculature of the distal esophagus and that Angiotensin II is a potent stimulator of esophageal contractions via the AT(1) receptor. The results suggest that Angiotensin II participates in the physiological control of the human esophageal motor activity.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiotensin II / pharmacology*
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage
  • Angiotensinogen / genetics
  • Benzimidazoles / administration & dosage
  • Biphenyl Compounds
  • Esophageal Sphincter, Lower / physiology*
  • Esophagus / physiology*
  • Female
  • Gene Expression
  • Humans
  • In Vitro Techniques
  • Male
  • Manometry
  • Middle Aged
  • Muscle Contraction / drug effects*
  • Peptidyl-Dipeptidase A / genetics
  • Peristalsis / drug effects
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Angiotensin, Type 2 / genetics
  • Receptor, Angiotensin, Type 2 / metabolism
  • Renin / genetics
  • Renin / metabolism
  • Tetrazoles / administration & dosage
  • Vasoconstrictor Agents / pharmacology*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Tetrazoles
  • Vasoconstrictor Agents
  • Angiotensinogen
  • Angiotensin II
  • Peptidyl-Dipeptidase A
  • Renin
  • candesartan